These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
203 related articles for article (PubMed ID: 29282890)
41. Measurable residual disease-guided treatment with azacitidine to prevent haematological relapse in patients with myelodysplastic syndrome and acute myeloid leukaemia (RELAZA2): an open-label, multicentre, phase 2 trial. Platzbecker U; Middeke JM; Sockel K; Herbst R; Wolf D; Baldus CD; Oelschlägel U; Mütherig A; Fransecky L; Noppeney R; Bug G; Götze KS; Krämer A; Bochtler T; Stelljes M; Groth C; Schubert A; Mende M; Stölzel F; Borkmann C; Kubasch AS; von Bonin M; Serve H; Hänel M; Dührsen U; Schetelig J; Röllig C; Kramer M; Ehninger G; Bornhäuser M; Thiede C Lancet Oncol; 2018 Dec; 19(12):1668-1679. PubMed ID: 30442503 [TBL] [Abstract][Full Text] [Related]
42. Therapy with low-dose azacitidine for MDS in children and young adults: a retrospective analysis of the EWOG-MDS study group. Cseh AM; Niemeyer CM; Yoshimi A; Catala A; Frühwald MC; Hasle H; van den Heuvel-Eibrink MM; Lauten M; De Moerloose B; Smith OP; Bernig T; Gruhn B; Kulozik AE; Metzler M; Olcay L; Suttorp M; Furlan I; Strahm B; Flotho C Br J Haematol; 2016 Mar; 172(6):930-6. PubMed ID: 26766110 [TBL] [Abstract][Full Text] [Related]
43. No clear survival benefit of azacitidine for lower-risk myelodysplastic syndromes: A retrospective study of Nagasaki. Toriyama E; Hata T; Yokota KI; Chiwata M; Kamijo R; Hashimoto M; Taguchi M; Horai M; Matsuo M; Matsuo E; Takasaki Y; Kawaguchi Y; Itonaga H; Sato S; Ando K; Sawayama Y; Taguchi J; Imaizumi Y; Tsushima H; Jo T; Yoshida S; Moriuchi Y; Miyazaki Y Cancer Sci; 2020 Dec; 111(12):4490-4499. PubMed ID: 32939867 [TBL] [Abstract][Full Text] [Related]
44. Results of treatment with azacitidine in patients aged ≥ 75 years included in the Spanish Registry of Myelodysplastic Syndromes. Xicoy B; Jiménez MJ; García O; Bargay J; Martínez-Robles V; Brunet S; Arilla MJ; Pérez de Oteyza J; Andreu R; Casaño FJ; Cervero CJ; Bailén A; Díez M; González B; Vicente AI; Pedro C; Bernal T; Luño E; Cedena MT; Palomera L; Simiele A; Calvo JM; Marco V; Gómez E; Gómez M; Gallardo D; Muñoz J; de Paz R; Grau J; Ribera JM; Benlloch LE; Sanz G Leuk Lymphoma; 2014 Jun; 55(6):1300-3. PubMed ID: 23952246 [TBL] [Abstract][Full Text] [Related]
45. Pharmacokinetics and Pharmacodynamics with Extended Dosing of CC-486 in Patients with Hematologic Malignancies. Laille E; Shi T; Garcia-Manero G; Cogle CR; Gore SD; Hetzer J; Kumar K; Skikne B; MacBeth KJ PLoS One; 2015; 10(8):e0135520. PubMed ID: 26296092 [TBL] [Abstract][Full Text] [Related]
46. Lack of objective response of myelodysplastic syndromes and acute myeloid leukemia to decitabine after failure of azacitidine. Duong VH; Bhatnagar B; Zandberg DP; Vannorsdall EJ; Tidwell ML; Chen Q; Baer MR Leuk Lymphoma; 2015 Jun; 56(6):1718-22. PubMed ID: 25263320 [TBL] [Abstract][Full Text] [Related]
48. Pharmacokinetics of decitabine administered as a 3-h infusion to patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). Cashen AF; Shah AK; Todt L; Fisher N; DiPersio J Cancer Chemother Pharmacol; 2008 Apr; 61(5):759-66. PubMed ID: 17564707 [TBL] [Abstract][Full Text] [Related]
49. Bone marrow hypocellularity does not affect tolerance or efficacy of azacitidine in patients with higher-risk myelodysplastic syndromes. Seymour JF; Bennett JM; List AF; Mufti GJ; Gore SD; Fenaux P; Santini V; Hetzer J; Songer S; Skikne BS; Beach CL Br J Haematol; 2014 Apr; 165(1):49-56. PubMed ID: 24467613 [TBL] [Abstract][Full Text] [Related]
50. Continued azacitidine therapy beyond time of first response improves quality of response in patients with higher-risk myelodysplastic syndromes. Silverman LR; Fenaux P; Mufti GJ; Santini V; Hellström-Lindberg E; Gattermann N; Sanz G; List AF; Gore SD; Seymour JF Cancer; 2011 Jun; 117(12):2697-702. PubMed ID: 21656747 [TBL] [Abstract][Full Text] [Related]
51. Maintenance treatment with azacytidine for patients with high-risk myelodysplastic syndromes (MDS) or acute myeloid leukaemia following MDS in complete remission after induction chemotherapy. Grövdal M; Karimi M; Khan R; Aggerholm A; Antunovic P; Astermark J; Bernell P; Engström LM; Kjeldsen L; Linder O; Nilsson L; Olsson A; Holm MS; Tangen JM; Wallvik J; Oberg G; Hokland P; Jacobsen SE; Porwit A; Hellström-Lindberg E Br J Haematol; 2010 Aug; 150(3):293-302. PubMed ID: 20497178 [TBL] [Abstract][Full Text] [Related]
52. Predicting outcome of patients with myelodysplastic syndromes after failure of azacitidine: validation of the North American MDS consortium scoring system. Prebet T; Fenaux P; Vey N; Haematologica; 2016 Oct; 101(10):e427-e428. PubMed ID: 27694503 [No Abstract] [Full Text] [Related]
53. Comparison between decitabine and azacitidine for the treatment of myelodysplastic syndrome: a meta-analysis with 1,392 participants. Xie M; Jiang Q; Xie Y Clin Lymphoma Myeloma Leuk; 2015 Jan; 15(1):22-8. PubMed ID: 25042977 [TBL] [Abstract][Full Text] [Related]
54. Phase 2 study of the lenalidomide and azacitidine combination in patients with higher-risk myelodysplastic syndromes. Sekeres MA; Tiu RV; Komrokji R; Lancet J; Advani AS; Afable M; Englehaupt R; Juersivich J; Cuthbertson D; Paleveda J; Tabarroki A; Visconte V; Makishima H; Jerez A; Paquette R; List AF; Maciejewski JP Blood; 2012 Dec; 120(25):4945-51. PubMed ID: 22915641 [TBL] [Abstract][Full Text] [Related]
55. Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study. DiNardo CD; Pratz KW; Letai A; Jonas BA; Wei AH; Thirman M; Arellano M; Frattini MG; Kantarjian H; Popovic R; Chyla B; Xu T; Dunbar M; Agarwal SK; Humerickhouse R; Mabry M; Potluri J; Konopleva M; Pollyea DA Lancet Oncol; 2018 Feb; 19(2):216-228. PubMed ID: 29339097 [TBL] [Abstract][Full Text] [Related]